drugset
drugset / Trial / NCT03101189

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

NCT03101189 ↗

Phase 1 Completed 40 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedSequentialQuadruple-blindOther

Summary

So far, ACT-541468 has been studied mainly in Caucasian subjects. The present study will bridge results obtained in Caucasian subjects to those in Japanese subjects.

Timeline

Start
2017-03-15
Primary completion
2017-04-24
Completion
2017-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg —
Subject Daridorexant Small molecule 50 mg —

Indications

No indication recorded.